Skip to content

Free cash flow at other companies

Abbott logo
AbbottABT
$916M-1.8%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.47B-56.6%
Boston Scientific logo
Boston ScientificBSX
$171M-51.7%
Medtronic logo
MedtronicMDT
$2.09B+0.8%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$24.67M+26.5%
ITG
Integer HoldingsITGR
$737K-87.8%

Other financials

Income statement

See full
Revenue$401.0K
Gross profit$31.0K
Operating income-$19.2M-6.1%
Net income-$18.6M-10.6%
EPS (diluted)-$0.49-2.1%

Balance sheet

See full
Cash & equivalents$68.3M-42.7%
Total debt$7.2M-16.6%
Total equity$66.3M-44.0%
Total assets$81.6M-38.8%

Cash flow

See full
Operating cash flow-$14.6M-7.9%
CapEx$33.0K-26.7%

Valuation

See full
Market cap$1.8B+38.4%
Enterprise value$1.73B+48.1%
P/S2,391.5×

Profitability

See full
Gross margin-4,067.5%
Operating margin-10,392.1%
Net margin-9,929%
FCF margin-7,390%

Returns & leverage

See full
Return on equity-80.7%+3.1pp
Debt / equity0.1×0.0×
Current ratio7.3×-8.3×

Where this comes from

Calculated from Pulse Biosciences, Inc.’s reported figures.

The official record: Pulse Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pulse Biosciences, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pulse Biosciences, Inc.'s free cash flow?
Pulse Biosciences, Inc. (PLSE) reported free cash flow of -$14.63M in Q1 2026.
How has Pulse Biosciences, Inc.'s free cash flow changed year-over-year?
Pulse Biosciences, Inc.'s free cash flow decreased by 7.8% year-over-year, from -$13.57M to -$14.63M.
What is the long-term trend for Pulse Biosciences, Inc.'s free cash flow?
Over 4 years (2021 to 2025), Pulse Biosciences, Inc.'s free cash flow has grown at a -0.0% compound annual growth rate (CAGR), from -$54.53M to -$54.44M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.